Background: Carbapenem-resistant Acinetobacter baumannii (CRAB) is a rapidly emerging,
life-threatening nosocomial infection. This study aimed to explore the risk factors, clinical …

Objective This study aimed to determine the clinical features, risk factors, and effective
antimicrobial therapy for Carbapenem-resistant Acinetobacter baumannii (CRAB) …

Background We retrospectively analyzed the effect of tigecycline and cefoperazone/
sulbactam therapies on the prognosis of patients with carbapenem-resistant Acinetobacter …

Background/Purpose Identification of risks of mortality for carbapenem-resistant
Acinetobacter baumannii (CRAB), with early implementation of an appropriate therapy, is …

Objectives Acinetobacter baumannii (A. baumannii) nosocomial infections represent a
serious hazard to public health, given high mortality rates and rapid spread of multidrug …

BACKGROUND: It is still controversial whether carbapenem-resistant Acinetobacter
baumannii (CRAB) is an independent risk factor for mortality. This study aimed to determine …

Nosocomial Acinetobacter baumannii bloodstream infections occur with significant
prevalence and mortality. The relationship between carbapenem resistance in A. baumannii …

BACKGROUND: Risk factors and outcome in patients who acquire nosocomial infections
due to carbapenem-resistant Acinetobacter baumannii (CRAB) are rarely investigated …

Introduction. Increasing evidence demonstrates unfavourable outcomes in bloodstream
infections (BSI) due to the carbapenem-resistant Acinetobacter baumannii complex (CRAB) …

Background It is unknown whether there are differences between bacteremia caused by
carbapenem resistant Acinetobacter baumannii (CRAB) and carbapenem resistant …